Display options
Cite
Giakoumettis D, Kritis A, Foroglou N. C6 cell line: the gold standard in glioma research. Hippokratia. 2018;22(3):105-112
Giakoumettis, D., Kritis, A., & Foroglou, N. (2018). C6 cell line: the gold standard in glioma research. Hippokratia, 22(3), 105-112.
Giakoumettis, D, et al. "C6 cell line: the gold standard in glioma research." Hippokratia vol. 22,3 (2018): 105-112.
Giakoumettis D, Kritis A, Foroglou N. C6 cell line: the gold standard in glioma research. Hippokratia. 2018 Jul-Sep;22(3):105-112. PMID: 31641331; PMCID: PMC6801124.
Copy Download .nbib Format: NLM
Share it on

Hippokratia. 2018 Jul-Sep;22(3):105-112.

C6 cell line: the gold standard in glioma research.

Hippokratia

D Giakoumettis, A Kritis, N Foroglou

Affiliations

  1. First Department of Neurosurgery, University of Athens Medical School, "Evangelismos" General Hospital, Athens.
  2. First Department of Neurosurgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  3. Laboratory of Physiology, Faculty of Medicine, School of Health Sciences.
  4. cGMP Regenerative Medicine facility, Department of Physiology and Pharmacology, Faculty of Medicine, School of Health Sciences.

PMID: 31641331 PMCID: PMC6801124

Abstract

BACKGROUND: Glioblastoma multiforme is the most aggressive brain tumor with poor prognosis and an average survival of 1-2 years. Animal models that simulate the features of human glioma are the key to newer agents or therapeutic strategies. In order to establish such models, the C6 glioma cell line has been mostly used in neuro-oncology research.

METHODS: In this narrative review, we systematically reviewed the international literature in order to retrieve and present the most important biological and molecular features of C6 cell line.

RESULTS: Even though many cell lines have been developed, each cell line presents with slight differences from human glioma behavior. C6 cancer cell line is a rat glioma cell line, which can simulate in overall the high growth rate, the high vascularization, and the highly infiltrative character of glioblastoma multiforme.

CONCLUSIONS: Most of the C6 glioma research has been focused on testing a wide diversity of agents for their tumoricidal activity. C6 cell line is considered to be a safe and popular glioma model in the literature, providing a good simulation of glioblastoma multiforme. HIPPOKRATIA 2018, 22(3): 105-112.

Copyright 2018, Hippokratio General Hospital of Thessaloniki.

Keywords: C6; cell line; glioblastoma multiforme; glioma; rat glioma model

Conflict of interest statement

Authors declare no conflicts of interest.

References

  1. J Neurooncol. 1989 Sep;7(3):299-304 - PubMed
  2. J Pharmacol Exp Ther. 2018 Jan;364(1):77-86 - PubMed
  3. Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 - PubMed
  4. PLoS One. 2015 Feb 06;10(2):e0116202 - PubMed
  5. Cancer Res. 1998 Jan 1;58(1):149-58 - PubMed
  6. J Cereb Blood Flow Metab. 1998 May;18(5):510-20 - PubMed
  7. Acta Cir Bras. 2012 Jun;27(6):383-7 - PubMed
  8. J Magn Reson Imaging. 2010 Aug;32(2):267-75 - PubMed
  9. Neuroreport. 2000 Sep 11;11(13):2855-60 - PubMed
  10. J Exp Clin Cancer Res. 2016 Nov 16;35(1):178 - PubMed
  11. J Chemother. 2008 Apr;20(2):253-62 - PubMed
  12. Neuro Oncol. 2008 Jun;10(3):292-9 - PubMed
  13. J Histochem Cytochem. 2002 Sep;50(9):1195-203 - PubMed
  14. Eur J Pharmacol. 2013 Oct 15;718(1-3):41-7 - PubMed
  15. Biomaterials. 2014 Apr;35(13):4133-45 - PubMed
  16. Neurosurgery. 1990 Apr;26(4):622-8 - PubMed
  17. J Neurooncol. 1995;24(2):181-8 - PubMed
  18. Oncol Rep. 2012 May;27(5):1348-52 - PubMed
  19. Neuroscience. 1990;34(3):687-97 - PubMed
  20. Cancer Lett. 2009 Feb 18;274(2):305-12 - PubMed
  21. Methods Mol Biol. 2017;1622:149-159 - PubMed
  22. J Neuroimmunol. 2003 Feb;135(1-2):1-9 - PubMed
  23. Exp Neurol. 2003 Aug;182(2):275-87 - PubMed
  24. J Biol Chem. 1994 Aug 19;269(33):21215-22 - PubMed
  25. Mol Cancer. 2010 Jun 01;9:135 - PubMed
  26. J Neurosci Res. 1990 Dec;27(4):689-96 - PubMed
  27. Photodiagnosis Photodyn Ther. 2014 Dec;11(4):603-12 - PubMed
  28. J Transl Med. 2005 Oct 19;3:38 - PubMed
  29. Ann Neurol. 2010 Dec;68(6):915-24 - PubMed
  30. Biochem Biophys Res Commun. 2011 Jul 1;410(2):218-23 - PubMed
  31. Gene Ther. 2000 Oct;7(20):1715-24 - PubMed
  32. J Neurosurg. 1997 Oct;87(4):602-9 - PubMed
  33. Clin Cancer Res. 2004 Dec 15;10(24):8561-76 - PubMed
  34. PLoS One. 2016 Dec 22;11(12):e0168174 - PubMed
  35. Acta Neuropathol. 1993;86(2):117-25 - PubMed
  36. Cancer Res. 2001 Feb 15;61(4):1717-26 - PubMed
  37. Exp Gerontol. 2014 Jun;54:47-52 - PubMed
  38. J Cell Biol. 1999 Jan 25;144(2):373-84 - PubMed
  39. Cancer Res. 1993 Jan 1;53(1):176-82 - PubMed
  40. J Neurooncol. 2000;46(2):105-14 - PubMed
  41. Cancer Lett. 2008 Aug 28;267(2):226-44 - PubMed
  42. Epilepsia. 2004 Dec;45(12):1525-30 - PubMed
  43. Nature. 1994 Feb 10;367(6463):576-9 - PubMed
  44. Biomed Rep. 2016 Apr;4(4):444-448 - PubMed
  45. J Coll Physicians Surg Pak. 2012 Nov;22(11):690-3 - PubMed
  46. In Vivo. 2012 Jul-Aug;26(4):571-6 - PubMed
  47. Can J Neurol Sci. 1981 Nov;8(4):325-31 - PubMed
  48. Cancer Res. 1993 Dec 1;53(23):5822-7 - PubMed
  49. Neuroimage. 2008 Apr 1;40(2):973-83 - PubMed
  50. Mol Biol Rep. 2014 Jun;41(6):3907-13 - PubMed
  51. Nat Rev Cancer. 2004 Jul;4(7):540-50 - PubMed
  52. J Neurooncol. 1998 Sep;39(3):205-16 - PubMed
  53. Acta Radiol. 2017 Sep;58(9):1138-1146 - PubMed
  54. Genes Dev. 2007 Nov 1;21(21):2683-710 - PubMed
  55. Neurochem Res. 2007 Dec;32(12):2235-42 - PubMed
  56. Mol Biol Cell. 2003 Apr;14(4):1468-78 - PubMed
  57. Int J Oncol. 2015 Apr;46(4):1739-47 - PubMed
  58. Pathobiology. 1999 Jul-Aug;67(4):202-6 - PubMed
  59. Neurol Res. 2008 Jun;30(5):511-7 - PubMed
  60. J Neurosurg. 1996 Jun;84(6):1033-8 - PubMed
  61. Am J Pathol. 2005 Aug;167(2):565-76 - PubMed
  62. World Neurosurg. 2019 Feb;122:e773-e782 - PubMed
  63. Hum Gene Ther. 1999 Jan 1;10(1):95-101 - PubMed
  64. Eur J Pharm Sci. 2017 Aug 30;106:185-197 - PubMed
  65. Leukemia. 1995 Oct;9 Suppl 1:S106-12 - PubMed
  66. Anticancer Res. 2014 Apr;34(4):1901-11 - PubMed
  67. Neuron. 2011 Jan 13;69(1):77-90 - PubMed
  68. N Engl J Med. 2008 Jul 31;359(5):492-507 - PubMed
  69. Sci Rep. 2017 Dec 14;7(1):17556 - PubMed
  70. J Neurosurg. 1995 Oct;83(4):665-71 - PubMed
  71. In Vitro Cell Dev Biol Anim. 2008 Jul-Aug;44(7):280-9 - PubMed
  72. Science. 1968 Jul 26;161(3839):370-1 - PubMed
  73. Neurosurg Focus. 2005 Oct 15;19(4):E1 - PubMed
  74. J Neurooncol. 1987;4(4):403-15 - PubMed
  75. Toxicol Appl Pharmacol. 2015 Jul 15;286(2):112-23 - PubMed
  76. J Biomed Nanotechnol. 2013 Mar;9(3):516-26 - PubMed
  77. Oncol Lett. 2015 Oct;10(4):2442-2446 - PubMed
  78. Cancer Res. 2010 Apr 15;70(8):3299-308 - PubMed
  79. Cancer Res. 1998 Oct 15;58(20):4654-9 - PubMed
  80. N Engl J Med. 2009 Feb 19;360(8):765-73 - PubMed
  81. Tomography. 2018 Jun;4(2):55-65 - PubMed
  82. Science. 1993 Jan 1;259(5091):94-7 - PubMed
  83. J Neurooncol. 2007 Nov;85(2):133-48 - PubMed
  84. J Biol Inorg Chem. 2014 Aug;19(6):1025-35 - PubMed
  85. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  86. Am J Pathol. 2003 Apr;162(4):1083-93 - PubMed
  87. Biotechnol Lett. 2012 Mar;34(3):441-6 - PubMed
  88. Cancer Res. 1996 Mar 15;56(6):1440-4 - PubMed
  89. PLoS One. 2018 Jul 26;13(7):e0201453 - PubMed
  90. NMR Biomed. 2012 Apr;25(4):685-94 - PubMed
  91. Cancer Lett. 2017 Aug 28;402:131-141 - PubMed
  92. Neurosurgery. 1991 May;28(5):652-8 - PubMed
  93. Cytotechnology. 2016 Mar;68(2):197-202 - PubMed
  94. J Neurosurg. 2008 May;108(5):972-8 - PubMed
  95. NMR Biomed. 2008 Nov;21(10):1043-56 - PubMed
  96. J Neurosurg. 1996 Jun;84(6):1013-9 - PubMed
  97. Histol Histopathol. 2009 Jul;24(7):879-91 - PubMed

Publication Types